Dishman Carbogen Amcis reported a significant deterioration in its financial performance for the first quarter of FY27, posting a consolidated net loss of ₹579 million. This marks a sharp reversal from the previous year, when the company recorded a net profit of ₹234 million in the same period. The swing to losses was primarily driven by the deferment of Contract Development and Manufacturing Organisation (CDMO) revenues and rising employee expenses.

Alongside the swing to losses, the company’s top-line growth stalled. Revenue for the quarter stood at ₹6,776 million, down 4.3% from ₹7,081 million recorded in the corresponding quarter of the prior fiscal year. The decline in revenue coincided with the emergence of the net loss, indicating pressure on the company’s bottom line despite relatively modest contraction in sales. Management attributed the revenue dip to customer-requested rescheduling of project deliverables worth approximately CHF 10 million to the second half of the financial year.

Segment Performance

The revenue contraction was concentrated in the CDMO segment, which is the company’s primary growth engine. CDMO revenue declined by 12.6% year-on-year to ₹5,344 million from ₹6,113 million. This segment contributed 79% of total revenue in Q1FY27, down from 83% in FY26. Conversely, the Marketable Molecules (MM) segment saw robust growth, with revenue increasing by 48% to ₹1,433 million from ₹968 million, driven largely by higher Cholesterol sales.

Margin Compression

EBITDA margin contracted sharply to 8.9% in Q1FY27, compared with 19.9% in Q1FY26. The absolute EBITDA fell by 57.3% to ₹601 million from ₹1,407 million. The margin compression in the CDMO segment was severe, dropping to 6.3% from 17.9%, as the cost base remained largely fixed while revenues were deferred. Additionally, a notional foreign exchange loss of INR 117.3 million impacted margins. The MM segment margin also declined to 18.6% from 32.4%, though management noted these levels are in line with full-year FY26 margins.

Operating expenses rose during the quarter. Employee expenses increased by 10.6% to ₹3,891 million, while Cost of Goods Sold (COGS) rose by 16.5% to ₹1,142 million. Depreciation and amortization charges increased by 11.5% to ₹907 million. Finance costs decreased slightly by 13.3% to ₹371 million.

What the Numbers Show

The data reveals a structural vulnerability in the company’s cost structure during periods of revenue volatility. While revenue declined by only 4.3%, EBITDA plummeted by 57.3%. This disproportionate impact suggests that a significant portion of Dishman’s cost base—particularly employee expenses (₹3,891 million) and depreciation (₹907 million)—is fixed or semi-fixed. Consequently, even modest delays in project billing, such as the CHF 10 million deferment, can erase profitability entirely. The strong performance in the Marketable Molecules segment (up 48%) was insufficient to offset the drag from the larger CDMO business, highlighting the company’s continued heavy reliance on complex, long-cycle CDMO contracts for overall financial health.

Balance Sheet and Outlook

Net debt excluding lease liabilities stood at CHF 153.6 million as on June 30, 2026, an increase from CHF 146.8 million as on March 31, 2026. Capital expenditure during the quarter was CHF 4.9 million. The company maintains a global manufacturing footprint across India, Switzerland, UK, France, China, and the Netherlands, with 23 multi-purpose facilities and 32 R&D labs. Investors will need to monitor subsequent quarters to determine if the deferred CDMO revenues materialize in H2FY27, which would be critical for restoring profitability trends established in FY26.

Dishman Carbogen Amcis Ltd’s wholly-owned subsidiary, CARBOGEN AMCIS AG, has successfully commissioned a new ground-mounted photovoltaic system at its Neuland site in Switzerland. The new solar power plant, with a capacity of 1,200 kWp, comprises 2,448 photovoltaic modules installed on an area of approximately 6,200 m². This development underscores the company's commitment to sustainability and the expansion of renewable energy within its operations.

The facility is designed to be one of the most efficient conventional ground-mounted systems in the Swiss Mittelland region. Ground-mounted photovoltaic systems remain rare in Switzerland, making this a significant installation for an industrial site. The energy generated will be used primarily for on-site consumption, which is expected to sustainably reduce the company's CO2 emissions.

Project Details and Implementation

The project was executed in collaboration with energy and infrastructure partners IWB (Industrielle Werke Basel) and its subsidiary Planeco. These partners were responsible for the planning and implementation of the facility. The construction phase lasted three months, concluding with an official opening ceremony attended by government officials and company representatives.

Strategic Impact

Stephan Fritschi, Chief Executive Officer of CARBOGEN AMCIS, stated that the commissioning represents a targeted investment in a sustainable energy supply. The project is viewed as an important milestone in the company's path to implementing environmental goals. CARBOGEN AMCIS aims to continuously improve energy efficiency and increase the share of renewable energy in its production processes.

CARBOGEN AMCIS is a Switzerland-based pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company. It is a wholly owned subsidiary of Dishman Carbogen Amcis Ltd .